BiotechTube
AutoTissue

AutoTissue

Berlin, Germany· Est.
autotissue.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AutoTissue is a private, commercial-stage biotech company pioneering glutaraldehyde-free, decellularized tissue implants for cardiovascular repair. Its core technology platform removes cellular material to minimize immunogenicity, with its lead commercial product, the Matrix Patch™ equine, used in pediatric cardiac surgery and adult aortic valve repair. The company operates a hybrid business model, combining product sales with contract research and manufacturing services, and is actively developing next-generation products like a decellularized stented heart valve.

Cardiovascular

Technology Platform

Proprietary, glutaraldehyde-free process using deoxycholic acid (DOA) to decellularize biological tissue, creating an acellular extracellular matrix (ECM) scaffold with low immunogenicity and preserved mechanical properties.

Opportunities

The large and growing global market for cardiovascular implants, particularly the unmet need in pediatric surgery for durable, growth-compatible materials and the broad demand for superior alternatives to glutaraldehyde-fixed tissues in adult cardiac repair.
The development of a decellularized stented heart valve could allow entry into the multi-billion dollar surgical heart valve market.

Risk Factors

Long-term clinical data for decellularized implants is still maturing, requiring ongoing validation.
The company faces significant competition from large, established medtech players and must navigate complex regulatory pathways and reimbursement landscapes globally to achieve commercial scale.

Competitive Landscape

AutoTissue competes in the cardiovascular patch and tissue engineering segment against large medtech companies (e.g., Edwards Lifesciences, Abbott, Getinge) offering glutaraldehyde-treated tissues, as well as other developers of decellularized or engineered tissues. Its key differentiation is its specific glutaraldehyde-free, detergent-based decellularization process and its focus on pediatric applications.

More companies in Regenerative Medicine →More companies in Germany →